The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?

Advanced Drug Delivery Reviews

Volumn 61, Issue 14, 2009, Pages 1316-1323

  Lee, Junghee ^a,b   Boo, Jung Hyun ^c   Ryu, Hoon ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Neuroprotection; Parkinson's disease; Therapeutics

Indexed keywords

ALZHEIMER'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; HUNTINGTON'S DISEASE; NEUROPROTECTION; PARKINSON'S DISEASE;

ENZYME ACTIVITY; LIGANDS; MITOCHONDRIA;

DISEASES;

3 HYDROXYBUTYRIC ACID; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; ANTIOXIDANT; AVICIN DERIVATIVE; CALCINEURIN INHIBITOR; CARNITINE; CLIOQUINOL; CREATINE; CYCLOSPORIN A; CYSTAMINE; DEFEROXAMINE; DIMEBON; ESTRADIOL; ESTROGEN; KT 5720; MELATONIN; MINOCYCLINE; NEUROPROTECTIVE AGENT; NICOTINAMIDE; RESVERATROL; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIRTUIN; SZETO SCHILLER PEPTIDE; TACROLIMUS; THIOCTIC ACID; TRITERPENOID; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIOENERGY; CELL SURVIVAL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENERGY YIELD; HUMAN; HUNTINGTON CHOREA; LEARNING DISORDER; MEMORY DISORDER; MITOCHONDRIAL RESPIRATION; NERVE CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

DRUG DELIVERY SYSTEMS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES;

EID: 71549121668     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.07.016     Document Type: Review

References (130)

1. Saraste M. Oxidative phosphorylation at the fin de siecle. Science 283 (1999) 1488-1493
2. Nicholls D.G., and Ferguson S.J. Bioenergetics 2 (1992), Academic Press, London
3. Albers D.S., and Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm., Suppl. 59 (2000) 133-154
4. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., and Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13 (1993) 4181-4192
5. Zamzami N., and Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat. Rev., Mol. Cell Biol. 2 (2001) 67-71
6. Rowland L.P., and Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344 (2001) 1688-1700
7. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
8. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev., Neurosci. 2 (2001) 806-819
9. Poon H.F., Hensley K., Thongboonkerd V., Merchant M.L., Lynn B.C., Pierce W.M., Klein J.B., Calabrese V., and Butterfield D.A. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 39 (2005) 453-462
10. Schonhoff C.M., Matsuoka M., Tummala H., Johnson M.A., Estevez A.G., Wu R., Kamaid A., Ricart K.C., Hashimoto Y., Gaston B., Macdonald T.L., Xu Z., and Mannick J.B. S-nitrosothiol depletion in amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2404-2409
11. Jones J.M., Datta P., Srinivasula S.M., Ji W., Gupta S., Zhang Z., Davies E., Hajnoczky G., Saunders T.L., Van Keuren M.L., Fernandes-Alnemri T., Meisler M.H., and Alnemri E.S. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 425 (2003) 721-727
12. Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., Gunn-Moore F.J., Vonsattel J.P., Arancio O., Chen J.X., and Yan S.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 14 (2008) 1097-1105
13. Atamna H., and Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3381-3386
14. Huttunen H.J., Guenette S.Y., Peach C., Greco C., Xia W., Kim D.Y., Barren C., Tanzi R.E., and Kovacs D.M. HtrA2 regulates beta-amyloid precursor protein (APP) metabolism through endoplasmic reticulum-associated degradation. J. Biol. Chem. 282 (2007) 28285-28295
15. Liu M.L., Liu M.J., Shen Y.F., Ryu H., Kim H.J., Klupsch K., Downward J., and Hong S.T. Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-{beta}. J. Cell Sci. 122 (2009) 1917-1926
16. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
17. Bruyn G.W. Huntington's chorea. Tijdschr. Ziekenverpl. 32 (1979) 101-105
18. Spokes E.G., Garrett N.J., Rossor M.N., and Iversen L.L. Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. J. Neurol. Sci. 48 (1980) 303-313
19. Spokes E.G. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 103 (1980) 179-210
20. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler Jr. J.F., Greenamyre J.T., Snyder S.H., and Ross C.A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5 (1999) 1194-1198
21. Hansson O., Petersen A., Leist M., Nicotera P., Castilho R.F., and Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8727-8732
22. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., and Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene. Eur. J. Neurosci. 14 (2001) 1492-1504
23. Bogdanov M.B., Ferrante R.J., Kuemmerle S., Klivenyi P., and Beal M.F. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J. Neurochem. 71 (1998) 2642-2644
24. Zeron M.M., Chen N., Moshaver A., Lee A.T., Wellington C.L., Hayden M.R., and Raymond L.A. Mutant huntingtin enhances excitotoxic cell death. Mol. Cell. Neurosci. 17 (2001) 41-53
25. Schiefer J., Landwehrmeyer G.B., Luesse H.G., Sprunken A., Puls C., Milkereit A., Milkereit E., and Kosinski C.M. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. 17 (2002) 748-757
26. Inagaki R., Tagawa K., Qi M.L., Enokido Y., Ito H., Tamura T., Shimizu S., Oyanagi K., Arai N., Kanazawa I., Wanker E.E., and Okazawa H. Omi/HtrA2 is relevant to the selective vulnerability of striatal neurons in Huntington's disease. Eur. J. Neurosci. 28 (2008) 30-40
27. Foley P., and Riederer P. Pathogenesis and preclinical course of Parkinson's disease. J. Neural Transm., Suppl. 56 (1999) 31-74
28. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 (1989) 1269
29. Gu M., Cooper J.M., Taanman J.W., and Schapira A.H. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol. 44 (1998) 177-186
30. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., and Schapira A.H. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36 (1994) 876-881
31. Vila M., and Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 4 (2003) 365-375
32. Strauss K.M., Martins L.M., Plun-Favreau H., Marx F.P., Kautzmann S., Berg D., Gasser T., Wszolek Z., Muller T., Bornemann A., Wolburg H., Downward J., Riess O., Schulz J.B., and Krüger R. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 14 (2005) 2099-2111
33. Martins L.M., Morrison A., Klupsch K., Fedele V., Moisoi N., Teismann P., Abuin A., Grau E., Geppert M., Livi G.P., Creasy C.L., Martin A., Hargreaves I., Heales S.J., Okada H., Brandner S., Schulz J.B., Mak T., and Downward J. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol. Cell. Biol. 24 (2004) 9848-9862
34. Murphy M.P., and Smith R.A. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug Deliv. Rev. 41 (2000) 235-250
35. Murphy M.P. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol. 15 (1997) 326-330
36. Nicotera P., Leist M., and Ferrando-May E. Intracellular ATP, a switch in the decision between apoptosis and necrosis. Toxicol. Lett. 102-103 (1998) 139-142
37. Leist M., and Nicotera P. The shape of cell death. Biochem. Biophys. Res. Commun. 236 (1997) 1-9
38. Bernardi P. Mitochondria in muscle cell death. Ital. J. Neurol. Sci. 20 (1999) 395-400
39. Friberg H., Ferrand-Drake M., Bengtsson F., Halestrap A.P., and Wieloch T. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J. Neurosci. 18 (1998) 5151-5159
40. Beal M.F., and Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev., Neurosci. 5 (2004) 373-384
41. Chan T.S., Wilson J.X., and O'Brien P.J. Coenzyme Q cytoprotective mechanisms. Methods Enzymol. 382 (2004) 89-104
42. Matthews R.T., Yang L., Browne S., Baik M., and Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8892-8897
43. Beal M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembranes 36 (2004) 381-386
44. Ferrante K.L., Shefner J., Zhang H., Betensky R., O'Brien M., Yu H., Fantasia M., Taft J., Beal M.F., Traynor B., Newhall K., Donofrio P., Caress J., Ashburn C., Freiberg B., O'Neill C., Paladenech C., Walker T., Pestronk A., Abrams B., Florence J., Renna R., Schierbecker J., Malkus B., and Cudkowicz M. Tolerance of high-dose (3000 mg/day) coenzyme Q10 in ALS. Neurology 65 (2005) 1834-1836
45. Beal M.F., Henshaw D.R., Jenkins B.G., Rosen B.R., and Schulz J.B. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. 36 (1994) 882-888
46. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., and Beal M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22 (2002) 1592-1599
47. O'Gorman E., Beutner G., Dolder M., Koretsky A.P., Brdiczka D., and Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 414 (1997) 253-257
48. Bessman S.P., and Geiger P.J. Transport of energy in muscle: the phosphorylcreatine shuttle. Science 211 (1981) 448-452
49. Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Mueller G., Wermer M., Kaddurah-Daouk R., and Beal M.F. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5 (1999) 347-350
50. Koroshetz W.J., Jenkins B.G., Rosen B.R., and Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41 (1997) 160-165
51. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., and Beal M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8 (2001) 479-491
52. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., and Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20 (2000) 4389-4397
53. Jang M.H., Jung S.B., Lee M.H., Kim C.J., Oh Y.T., Kang I., Kim J., and Kim E.H. Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells. Neurosci. Lett. 380 (2005) 26-31
54. Weishaupt J.H., Bartels C., Polking E., Dietrich J., Rohde G., Poeggeler B., Mertens N., Sperling S., Bohn M., Huther G., Schneider A., Bach A., Sirén A.L., Hardeland R., Bähr M., Nave K.A., and Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res. 41 (2006) 313-323
55. Brusco L.I., Marquez M., and Cardinali D.P. Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J. Pineal Res. 25 (1998) 260-263
56. Feng Z., and Zhang J.T. Melatonin reduces amyloid beta-induced apoptosis in pheochromocytoma (PC12) cells. J. Pineal Res. 37 (2004) 257-266
57. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V.C., Sharp A.H., Persichetti F., Cattaneo E., and MacDonald M.E. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9 (2000) 2799-2809
58. Jou M.J., Peng T.I., Reiter R.J., Jou S.B., Wu H.Y., and Wen S.T. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J. Pineal Res. 37 (2004) 55-70
59. Andreassen O.A., Ferrante R.J., Dedeoglu A., and Beal M.F. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 12 (2001) 3371-3373
60. Karunakaran S., Diwakar L., Saeed U., Agarwal V., Ramakrishnan S., Iyengar S., and Ravindranath V. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J. 21 (2007) 2226-2236
61. Kasparova S., Sumbalova Z., Bystricky P., Kucharska J., Liptaj T., Mlynarik V., and Gvozdjakova A. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem. Int. 48 (2006) 93-99
62. Kira Y., Nishikawa M., Ochi A., Sato E., and Inoue M. L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res. 1070 (2006) 206-214
63. Lesort M., Lee M., Tucholski J., and Johnson G.V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278 (2003) 3825-3830
64. Maczurek A., Hager K., Kenklies M., Sharman M., Martins R., Engel J., Carlson D.A., and Munch G. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv. Drug Deliv. Rev. 60 (2008) 1463-1470
65. Nishimura M., Okimura Y., Fujita H., Yano H., Lee J., Suzaki E., Inoue M., Utsumi K., and Sasaki J. Mechanism of 3-nitropropionic acid-induced membrane permeability transition of isolated mitochondria and its suppression by L-carnitine. Cell Biochem. Funct. 26 (2008) 881-891
66. Mao Z., Choo Y.S., and Lesort M. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur. J. Neurosci. 23 (2006) 1701-1710
67. Testa C.M., Sherer T.B., and Greenamyre J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res. 134 (2005) 109-118
68. Wang C., Sadovova N., Ali H.K., Duhart H.M., Fu X., Zou X., Patterson T.A., Binienda Z.K., Virmani A., Paule M.G., Slikker Jr. W., and Ali S.F. L-carnitine protects neurons from 1-methyl-4-phenylpyridinium-induced neuronal apoptosis in rat forebrain culture. Neuroscience 144 (2007) 46-55
69. Binienda Z., Przybyla-Zawislak B., Virmani A., and Schmued L. L-carnitine and neuroprotection in the animal model of mitochondrial dysfunction. Ann. N.Y. Acad. Sci. 1053 (2005) 174-182
70. Ryu H., Lee J., Impey S., Ratan R.R., and Ferrante R.J. Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13915-13920
71. Weaver Jr. C.E., Park-Chung M., Gibbs T.T., and Farb D.H. 17beta-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res. 761 (1997) 338-341
72. Montal M. Mitochondria, glutamate neurotoxicity and the death cascade. Biochim. Biophys. Acta 1366 (1998) 113-126
73. Kajta M., Lason W., Bien E., and Marszal M. Neuroprotective effects of estrone on NMDA-induced toxicity in primary cultures of rat cortical neurons are independent of estrogen receptors. Pol. J. Pharmacol. 54 (2002) 727-729
74. Linford N.J., and Dorsa D.M. 17beta-Estradiol and the phytoestrogen genistein attenuate neuronal apoptosis induced by the endoplasmic reticulum calcium-ATPase inhibitor thapsigargin. Steroids 67 (2002) 1029-1040
75. Dribben W., Nemmers B., Nardi A., Taylor G., Olney J., and Farber N. Chronic but not acute estradiol treatment protects against the neurodegenerative effects of N-methyl-D-aspartate receptor antagonists. Endocrine 21 (2003) 53-58
76. Xue B., and Hay M. 17beta-estradiol inhibits excitatory amino acid-induced activity of neurons of the nucleus tractus solitarius. Brain Res. 976 (2003) 41-52
77. Mendez P., Azcoitia I., and Garcia-Segura L.M. Estrogen receptor alpha forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain. Brain Res. Mol. Brain Res. 112 (2003) 170-176
78. Yu X., Rajala R.V., McGinnis J.F., Li F., Anderson R.E., Yan X., Li S., Elias R.V., Knapp R.R., Zhou X., and Cao W. Involvement of insulin/phosphoinositide 3-kinase/Akt signal pathway in 17 beta-estradiol-mediated neuroprotection. J. Biol. Chem. 279 (2004) 13086-13094
79. Schultz T.W., Sinks G.D., and Cronin M.T. Structure-activity relationships for gene activation oestrogenicity: evaluation of a diverse set of aromatic chemicals. Environ. Toxicol. 17 (2002) 14-23
80. Green P.S., Gordon K., and Simpkins J.W. Phenolic A ring requirement for the neuroprotective effects of steroids. J. Steroid Biochem. Mol. Biol. 63 (1997) 229-235
81. Murashov A.K., Islamov R.R., McMurray R.J., Pak E.S., and Weidner D.A. Estrogen increases retrograde labeling of motoneurons: evidence of a nongenomic mechanism. Am. J. Physiol., Cell Physiol. 287 (2004) C320-C326
82. Stroppolo A., Tian C., Guinea B., Olm V., Sheffield R., Sommer J., and Ehrlich M.E. 17beta-Estradiol promotes striatal medium size spiny neuronal maturation in vitro. Neuroendocrinology 79 (2004) 259-267
83. Yager J.D., and Chen J.Q. Mitochondrial estrogen receptors-new insights into specific functions. Trends Endocrinol. Metab. 18 (2007) 89-91
84. Chen J.Q., and Yager J.D. Estrogen's effects on mitochondrial gene expression: mechanisms and potential contributions to estrogen carcinogenesis. Ann. N.Y. Acad. Sci. 1028 (2004) 258-272
85. Chen O.S., Crisp R.J., Valachovic M., Bard M., Winge D.R., and Kaplan J. Transcription of the yeast iron regulon does not respond directly to iron but rather to iron-sulfur cluster biosynthesis. J. Biol. Chem. 279 (2004) 29513-29518
86. Yang S.H., Liu R., Perez E.J., Wen Y., Stevens Jr. S.M., Valencia T., Brun-Zinkernagel A.M., Prokai L., Will Y., Dykens J., Koulen P., and Simpkins J.W. Mitochondrial localization of estrogen receptor beta. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4130-4135
87. Leong H., Riby J.E., Firestone G.L., and Bjeldanes L.F. Potent ligand-independent estrogen receptor activation by 3,3'-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways. Mol. Endocrinol. 18 (2004) 291-302
88. Farhat M.Y., Lavigne M.C., and Ramwell P.W. The vascular protective effects of estrogen. FASEB J. 10 (1996) 615-624
89. Almeida S., Domingues A.i., Rodrigues L., Oliveira C.R., and Rego A.C. FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol. Dis. 17 (2004) 435-444
90. Keep M., Elm E., Fong K.S.K., and Csiszar K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 894 (2001) 327-331
91. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A., Dawson V.L., Dawson T.M., and Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10 (2001) 919-926
92. Wang Y., Branicky R., Stepanyan Z., Carroll M., Guimond M.P., Hihi A., Hayes S., McBride K., and Hekimi S. The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. J. Biol. Chem. 284 (2009) 314-323
93. Moon Y., Lee K.H., Park J.H., Geum D., and Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J. Neurochem. 93 (2005) 1199-1208
94. Yang X., Yang Y., Li G., Wang J., and Yang E.S. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J. Mol. Neurosci. 34 (2008) 165-171
95. Dhanasekaran A., Kotamraju S., Kalivendi S.V., Matsunaga T., Shang T., Keszler A., Joseph J., and Kalyanaraman B. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J. Biol. Chem. 279 (2004) 37575-37587
96. Lu C., Zhang D., Whiteman M., and Armstrong J.S. Is antioxidant potential of the mitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA?. Antioxid. Redox Signal. 10 (2008) 651-660
97. Dedeoglu J.K.K.A., Yang L., Ferrante K.L., Hersch S.M., Beal M.F., and Ferrante R.J. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 85 (2003) 1359-1367
98. Brewer G.J., and Wallimann T.W. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J. Neurochem. 74 (2000) 1968-1978
99. Dupuis L., Oudart H., Rene F., Gonzalez de Aguilar J.L., and Loeffler J.P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11159-11164
100. Matthews R.T., Ferrante R.J., Klivenyi P., Yang L., Klein A.M., Mueller G., Kaddurah-Daouk R., and Beal M.F. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157 (1999) 142-149
101. Gonzalez-Polo R.A., Soler G., Rodriguezmartin A., Moran J.M., and Fuentes J.M. Protection against MPP+ neurotoxicity in cerebellar granule cells by antioxidants. Cell Biol. Int. 28 (2004) 373-380
102. Sangchot P., Sharma S., Chetsawang B., Porter J., Govitrapong P., and Ebadi M. Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev. Neurosci. 24 (2002) 143-153
103. Bachurin S., Bukatina E., Lermontova N., Tkachenko S., Afanasiev A., Grigoriev V., Grigorieva I., Ivanov Y., Sablin S., and Zefirov N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. N.Y. Acad. Sci. 939 (2001) 425-435
104. Bachurin S.O., Shevtsova E.P., Kireeva E.G., Oxenkrug G.F., and Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann. N.Y. Acad. Sci. 993 (2003) 334-344 discussion 345-349
105. Burns A., and Jacoby R. Dimebon in Alzheimer's disease: old drug for new indication. Lancet 372 (2008) 179-180
106. Imamura T.T.K., Kashiwaya Y., Nakaso K., and Nakashima K. D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease. J. Neurosci. Res. 84 (2006) 1376-1384
107. Tieu K., Perier C., Caspersen C., Teismann P., Wu D.C., Yan S.D., Naini A., Vila M., Jackson-Lewis V., Ramasamy R., and Przedborski S. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J. Clin. Invest. 112 (2003) 892-901
108. Wang X., Figueroa B.E., Stavrovskaya I.G., Zhang Y., Sirianni A.C., Zhu S., Day A.L., Kristal B.S., and Friedlander R.M. Methazolamide and melatonin inhibit mitochondrial cytochrome c release and are neuroprotective in experimental models of ischemic injury. Stroke 40 (2009) 1877-1885
109. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskaya I.G., Cattaneo E., Ferrante R.J., Kristal B.S., and Friedlander R.M. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10483-10487
110. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., and Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
111. Hallows W.C., Lee S., and Denu J.M. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 10230-10235
112. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., Rodgers J.T., Delalle I., Baur J.A., Sui G., Armour S.M., et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26 (2007) 3169-3179
113. Okawara M., Katsuki H., Kurimoto E., Shibata H., Kume T., and Akaike A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. Pharmacol. 73 (2007) 550-560
114. Outeiro T.F., Marques O., and Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim. Biophy. Acta 1782 (2008) 363-369
115. Parker J.A., Arango M., Abderrahmane S., Lambert E., Tourette C., Catoire H., and Neri C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37 (2005) 349-350
116. Qin W., Yang T., Ho L., Zhao Z., Wang J., Chen L., Zhao W., Thiyagarajan M., MacGrogan D., Rodgers J.T., Puigserver P., Sadoshima J., Deng H., Pedrini S., Gandy S., Sauve A.A., and Pasinetti G.M. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 281 (2006) 21745-21754
117. Schlicker C., Gertz M., Papatheodorou P., Kachholz B., Becker C.F.W., and Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J. Mol. Biol. 382 (2008) 790-801
118. Westphal C.H., Dipp M.A., and Guarente L. A therapeutic role for sirtuins in diseases of aging?. Trends Biochem. Sci. 32 (2007) 555-560
119. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R.A., Martinez G., Inestrosa N.C., and Bronfman M. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 282 (2007) 37006-37015
120. Jung T.W., Lee J.Y., Shim W.S., Kang E.S., Kim S.K., Ahn C.W., Lee H.C., and Cha B.S. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J. Neurol. Sci. 253 (2007) 53-60
121. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., and Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191 (2005) 331-336
122. Quintanilla R.A., Jin Y.N., Fuenzalida K., Bronfman M., and Johnson G.V.W. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J. Biol. Chem. 283 (2008) 25628-25637
123. Santos M.J., Quintanilla R.A., Toro A., Grandy R., Dinamarca M.C., Godoy J.A., and Inestrosa N.C. Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J. Biol. Chem. 280 (2005) 41057-41068
124. Szeto H.H. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 8 (2006) E277-E283
125. Szeto H.H. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J. 8 (2006) E521-E531
126. Szeto H.H. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann. N.Y. Acad. Sci. 1147 (2008) 112-121
127. Yang L., Zhao K., Calingasan N.Y., Luo G., Szeto H.H., and Beal F. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid. Redox Signal. 11 (2009) 1-10
128. Haridas V., Hanausek M., Nishimura G., Soehnge H., Gaikwad A., Narog M., Spears E., Zoltaszek R., Walaszek Z., and Gutterman J.U. Triterpenoid electrophiles (avicins) activate the innate stress response by redox regulation of a gene battery. J. Clin. Invest. 113 (2004) 65-73
129. Haridas V., Li X., Mizumachi T., Higuchi M., Lemeshko V.V., Colombini M., and Gutterman J.U. Avicins, a novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane. Mitochondrion 7 (2007) 234-240
130. 2+ efflux from the organelle. Ann. N.Y. Acad. Sci. 1147 (2008) 264-274